N-(3-氯-4-甲基苯)-4-氟苯甲酰胺,97 | 330469-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-氯-4-甲基苯)-4-氟苯甲酰胺,97
• 中文别名: N-(3-氯-4-甲基苯基)-4-氟苯甲酰胺
• 英文名称: N-(3-chloro-4-methylphenyl)-4-fluorobenzamide
• CAS: 330469-22-2
• 化学式: C₁₄H₁₁ClFNO
• mdl: MFCD01182509
• 分子量: 263.699
• InChiKey: HPUUMOIZAZANCN-UHFFFAOYSA-N

物化性质

• 沸点：
  302.8±42.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-(3-氯-4-甲基苯)-4-氟苯甲酰胺,97 在 盐酸 、 水 、 sodium hydride 、 溶剂黄146 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 37.5h， 生成 (±)-N-(3-chloro-4-methylphenyl)-4-fluoro-N-(3-(4-(4-fluorobenzyl)-2-methylpiperazin-1-yl)propyl)benzamide
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists

  摘要：

  Three series of novel 2-methylpiperazine derivatives were designed and synthesized using a fragment-assembly strategy. Among them, six compounds (13, 16, 18, 22, 33, and 36) showed potent activity against CCR5 comparable to that of the positive control, maraviroc, in calcium mobilization assay. Moreover, some compounds were selected and further tested for their antiviral activity in HIV-1 single cycle assay. As a result, four compounds (13, 16, 33, and 36) showed antiviral activity at the nanomolar level. Additionally, the potent four compounds showed no cytotoxicity at a concentration of 10 mu M. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.052
• 作为产物：
  描述：

  对氟苯甲酸 、 3-氯-4-甲基苯胺 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以87%的产率得到N-(3-氯-4-甲基苯)-4-氟苯甲酰胺,97
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists

  摘要：

  Three series of novel 2-methylpiperazine derivatives were designed and synthesized using a fragment-assembly strategy. Among them, six compounds (13, 16, 18, 22, 33, and 36) showed potent activity against CCR5 comparable to that of the positive control, maraviroc, in calcium mobilization assay. Moreover, some compounds were selected and further tested for their antiviral activity in HIV-1 single cycle assay. As a result, four compounds (13, 16, 33, and 36) showed antiviral activity at the nanomolar level. Additionally, the potent four compounds showed no cytotoxicity at a concentration of 10 mu M. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.052

文献信息

• Anti-infective compounds
  申请人：Brodin Priscille

  公开号：US20110178077A1

  公开（公告）日：2011-07-21

  The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.

  本发明涉及小分子化合物及其在治疗细菌感染，特别是结核病方面的用途。
• US8785452B2
  申请人：——

  公开号：US8785452B2

  公开（公告）日：2014-07-22
• Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists
  作者：Suwen Hu、Zhilong Wang、Tingjun Hou、Xiaodong Ma、Jing Li、Tao Liu、Xin Xie、Yongzhou Hu

  DOI：10.1016/j.bmc.2014.12.052

  日期：2015.3

  Three series of novel 2-methylpiperazine derivatives were designed and synthesized using a fragment-assembly strategy. Among them, six compounds (13, 16, 18, 22, 33, and 36) showed potent activity against CCR5 comparable to that of the positive control, maraviroc, in calcium mobilization assay. Moreover, some compounds were selected and further tested for their antiviral activity in HIV-1 single cycle assay. As a result, four compounds (13, 16, 33, and 36) showed antiviral activity at the nanomolar level. Additionally, the potent four compounds showed no cytotoxicity at a concentration of 10 mu M. (C) 2015 Elsevier Ltd. All rights reserved.